# ENZON PHARMACEUTICALS, INC. (ENZND) — merger [completed]
Source: SEC API (secapi.ai) · situation sit_14e0ba7cb14fdcb3cbab · retrieved 2026-08-11T15:51:37.280Z

## Overview
Enzon Pharmaceuticals, Inc. is a biological products company engaged in pharmaceutical development and operations.

On March 9, 2026, Enzon Pharmaceuticals announced an extension to the expiration date of its exchange offer to holders of Series C Non-Convertible Redeemable Preferred Stock, $0.01 par value per share. Under the offer, holders may exchange their Series C Preferred Stock for shares of Enzon's common stock, $0.01 par value per share. The extended expiration date is one minute after 11:59 p.m., Eastern time, on March 11, 2026, unless further extended.

## Terms
- Counterparty: Viskase Companies, Inc. · Consideration: stock

## Key dates
- Announced 2026-02-11 · Record 2026-01-29 · Vote 2026-02-11 · Expiry 2026-03-11 · Completed 2026-03-26

## Timeline
- 2026-02-11 · 425 (0001104659-26-013514): 425 - ENZON PHARMACEUTICALS, INC. — *Enzon Pharmaceuticals, Inc. is a biological products company (SIC 2836) engaged in the development and commercialization of pharmaceutical products.* On February 11, 2026, Enzon Pharmaceuticals, Inc. announced that stockholders approved two proposals via consent solicitation: (1) a 1-for-100 reverse stock split of Enzon Common Stock, approved by holders of 40,993,338 shares (55.2% of outstanding); and (2) adoption of the Agreement and Plan of Merger, dated June 20, 2025, as amended October 24, 2025, by and among Enzon, Viskase Companies, Inc., and EPSC Acquisition Corp., approved by holders of 42,350,448 shares (57.1% of outstanding). The consent solicitation concluded on February 11, 2026 at 8:00 a.m. Eastern Time, with the record date for voting being January 29, 2026, when 74,214,603 shares of Enzon Common Stock were outstanding and entitled to vote. Closing of the merger is subject to satisfaction or waiver of remaining conditions set forth in the Merger Agreement.
  https://www.sec.gov/Archives/edgar/data/727510/0001104659-26-013514.txt
- 2026-03-09 · 425 (0001104659-26-025226): 425 - ENZON PHARMACEUTICALS, INC. — *Enzon Pharmaceuticals, Inc. is a biological products company engaged in pharmaceutical development and operations.* On March 9, 2026, Enzon Pharmaceuticals announced an extension to the expiration date of its exchange offer to holders of Series C Non-Convertible Redeemable Preferred Stock, $0.01 par value per share. Under the offer, holders may exchange their Series C Preferred Stock for shares of Enzon's common stock, $0.01 par value per share. The extended expiration date is one minute after 11:59 p.m., Eastern time, on March 11, 2026, unless further extended.
  https://www.sec.gov/Archives/edgar/data/727510/0001104659-26-025226.txt
- 2026-03-26 · 8-K (0001104659-26-035301): 8-K FORM 8-K
  https://www.sec.gov/Archives/edgar/data/727510/000110465926035301/tm269894d1_8k.htm

## Citations
- 0001104659-26-013514 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465926013514
- 0001104659-26-025226 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465926025226
- 0001104659-26-035301 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465926035301